Pharmacodynamics and pharmacokinetics of DX-9065a in renal impairment.

被引：0
|
作者：
Depasse, F
Kunitada, S
Busson, J
Haque, N
Samama, MM
机构：
[1] LCL, Ivry, France
[2] Daiichi Pharmaceut Co Ltd, London, England
[3] Hop Hotel Dieu, Serv Hematol Biol, Paris, France
[4] Daiichi Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页码：121B / 121B
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment
    K. M. Koch
    M. Liu
    I. M. Davis
    S. Shaw
    Y. Yin
    European Journal of Clinical Pharmacology, 1997, 52 : 229 - 234
  • [22] Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment
    Koch, KM
    Liu, M
    Davis, M
    Shaw, S
    Yin, Y
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (03) : 229 - 234
  • [23] Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment
    Sanderink, GJ
    Guimart, C
    Jariwala, N
    Shukla, U
    Ozoux, ML
    Boutouyrie, B
    Hutman, HW
    Gutierrez, M
    Marbury, T
    Preston, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 229A - 229A
  • [24] A convenient and efficient synthesis of the blood coagulation factor Xa inhibitor (±)DX-9065a
    Davion, Yann
    Guillaumet, Gerald
    Lafosse, Michel
    Lesur, Brigitte
    Merour, Jean-Yves
    Finaru, Adriana
    REVISTA DE CHIMIE, 2006, 57 (08): : 850 - 855
  • [25] Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease
    Becker, RC
    Alexander, J
    Dyke, CK
    Harrington, RA
    THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) : 1182 - 1193
  • [26] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    DIABETOLOGIA, 2002, 45 : A259 - A260
  • [27] Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
    K.L. Rogers
    L. Chi
    S.T. Rapundalo
    J.B. Kramer
    K.P. Gallagher
    Basic Research in Cardiology, 1999, 94 : 15 - 22
  • [28] Pharmacokinetics of zileuton and its metabolites in subjects with renal impairment.
    Awni, WM
    Wong, S
    Chu, SY
    Patterson, K
    Hansen, R
    Machinist, JM
    Drajesk, J
    Keane, WF
    Halstenson, CE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII90 - PII90
  • [29] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF QUINAPRIL AND QUINAPRILAT IN RENAL IMPAIRMENT
    BEGG, EJ
    ROBSON, RA
    BAILEY, RR
    LYNN, KL
    FRANK, GJ
    OLSON, SC
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) : 213 - 220
  • [30] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF NICARDIPINE IN PATIENTS WITH RENAL IMPAIRMENT
    AHMED, JH
    ELLIOTT, HL
    GRANT, AC
    RODGER, RSC
    REID, JL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (01) : P145 - P146
12345